BRPI0606506A2 - polipeptìdeos de yersinia spp. e métodos de uso - Google Patents

polipeptìdeos de yersinia spp. e métodos de uso

Info

Publication number
BRPI0606506A2
BRPI0606506A2 BRPI0606506-6A BRPI0606506A BRPI0606506A2 BR PI0606506 A2 BRPI0606506 A2 BR PI0606506A2 BR PI0606506 A BRPI0606506 A BR PI0606506A BR PI0606506 A2 BRPI0606506 A2 BR PI0606506A2
Authority
BR
Brazil
Prior art keywords
polypeptides
methods
yersinia spp
yersinia
spp
Prior art date
Application number
BRPI0606506-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Daryll A Emery
Darren E Straub
Laura Wonderling
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Publication of BRPI0606506A2 publication Critical patent/BRPI0606506A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0606506-6A 2005-01-21 2006-01-20 polipeptìdeos de yersinia spp. e métodos de uso BRPI0606506A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64610605P 2005-01-21 2005-01-21
PCT/US2006/002474 WO2006079076A2 (en) 2005-01-21 2006-01-20 Yersinia spp. polypeptides and methods of use

Publications (1)

Publication Number Publication Date
BRPI0606506A2 true BRPI0606506A2 (pt) 2009-06-30

Family

ID=36649588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606506-6A BRPI0606506A2 (pt) 2005-01-21 2006-01-20 polipeptìdeos de yersinia spp. e métodos de uso

Country Status (12)

Country Link
US (8) US8563004B2 (enExample)
EP (3) EP2431382A1 (enExample)
JP (3) JP2008528512A (enExample)
CN (1) CN101142230A (enExample)
AU (1) AU2006206234B2 (enExample)
BR (1) BRPI0606506A2 (enExample)
CA (1) CA2595163A1 (enExample)
DK (1) DK1848732T3 (enExample)
ES (1) ES2588010T3 (enExample)
MX (1) MX2007008723A (enExample)
NZ (1) NZ556651A (enExample)
WO (1) WO2006079076A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279511T3 (es) * 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
DK1353689T3 (da) * 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
CA2595163A1 (en) 2005-01-21 2006-07-27 Epitopix, Llc Yersinia peptides grown in media comprising 2,2'-dipyridyl, compositions and kits thereof
KR102211724B1 (ko) 2011-05-31 2021-02-03 허치슨 바이오필름 메디컬 솔루션스 리미티드 세포 응집물의 분산 및 분리
US9631221B1 (en) * 2011-09-02 2017-04-25 Becton, Dickinson And Company Identification of microorganisms using MALDI-TOF-MS on-plate extraction
WO2013099806A1 (ja) 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
US9701760B2 (en) * 2012-02-13 2017-07-11 National University Corporation Kyoto Institute Of Technology Peptide having affinity for silicon nitride (Si3N4), and use therefor
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US9017953B2 (en) * 2012-05-18 2015-04-28 Washington University Biomarker and therapeutic for urinary tract infection
RU2549712C1 (ru) * 2013-11-26 2015-04-27 Федеральное казенное учреждение здравоохранения "Ростовский-на-Дону ордена Трудового Красного Знамени научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека CПОСОБ ВЫДЕЛЕНИЯ ИНГИБИТОРА СЕКРЕЦИИ СИДЕРОФОРОВ, СИНТЕЗИРУЕМОГО pgm- ШТАММАМИ Y. pestis И ВЫДЕЛЕННЫЙ ИНГИБИТОР
FR3024903A1 (fr) 2014-08-14 2016-02-19 Biomerieux Sa Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse
WO2016058007A2 (en) * 2014-10-10 2016-04-14 Rare Element Resources, Ltd. Processing for the extraction of rare earth elements
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
EP3373964A1 (en) 2015-11-09 2018-09-19 Epitopix, LLC Polypeptides of fusobacterium and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
MX2019009409A (es) 2017-02-10 2019-09-27 Epitopix Llc Proteinas y composiciones de inmunizacion que contienen proteinas de pasteurella y metodos de uso.
AU2020367821A1 (en) * 2019-10-18 2022-05-12 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN113679829B (zh) * 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
ES2279511T3 (es) * 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
US5830479A (en) 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
AU1860095A (en) 1994-03-22 1995-10-09 Pfizer Inc. (pasteurellaceae) antigens and related vaccines
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
WO1998024912A2 (en) * 1996-12-04 1998-06-11 Heska Corporation Recombinant plague vaccine
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
DK1353689T3 (da) 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0127657D0 (en) * 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
EP1784417B1 (en) 2004-08-25 2016-05-18 Epitopix, LLC Fusobacterium polypeptides and methods of use
CA2595163A1 (en) 2005-01-21 2006-07-27 Epitopix, Llc Yersinia peptides grown in media comprising 2,2'-dipyridyl, compositions and kits thereof
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006113907A2 (en) * 2005-04-20 2006-10-26 The General Hospital Corporation Escherichia coli o157:h7 proteins and uses thereof

Also Published As

Publication number Publication date
US20110206674A1 (en) 2011-08-25
AU2006206234B2 (en) 2012-01-12
DK1848732T3 (en) 2016-11-14
US20140170164A1 (en) 2014-06-19
EP2361926A3 (en) 2011-12-21
CN101142230A (zh) 2008-03-12
US9352029B2 (en) 2016-05-31
US20160228527A1 (en) 2016-08-11
US9109018B2 (en) 2015-08-18
EP2361926A2 (en) 2011-08-31
EP1848732B1 (en) 2016-07-27
AU2006206234A1 (en) 2006-07-27
US9085613B2 (en) 2015-07-21
JP2008528512A (ja) 2008-07-31
WO2006079076A3 (en) 2007-03-29
JP6224655B2 (ja) 2017-11-01
US20060269564A1 (en) 2006-11-30
JP2013018779A (ja) 2013-01-31
MX2007008723A (es) 2007-09-12
US20160051655A1 (en) 2016-02-25
US20140161834A1 (en) 2014-06-12
US9221899B2 (en) 2015-12-29
US20150307598A1 (en) 2015-10-29
JP2015193645A (ja) 2015-11-05
US9801932B2 (en) 2017-10-31
CA2595163A1 (en) 2006-07-27
NZ556651A (en) 2010-05-28
US20140161838A1 (en) 2014-06-12
US8563004B2 (en) 2013-10-22
JP6178059B2 (ja) 2017-08-09
US9085612B2 (en) 2015-07-21
WO2006079076A2 (en) 2006-07-27
ES2588010T3 (es) 2016-10-28
EP1848732A2 (en) 2007-10-31
EP2431382A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
ECSP10010722A (es) Compuestos orgánicos
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
MX384206B (es) Formulaciones de inhibidores de dpp iv
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
BRPI0821004A2 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
PA8792401A1 (es) Fenilendiaminas
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
SG158091A1 (en) Imidazoazepinone compounds
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL